Anebulo Pharmaceuticals (ANEB) Retained Earnings (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Retained Earnings of -$78.0 million for Q4 2025, down 11.32% year-over-year from -$88.0 million in Q4 2024, and down 2.63% quarter-over-quarter from -$76.0 million in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Retained Earnings (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Retained Earnings for 6 consecutive years, with -$78.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings fell 11.32% year-over-year to -$78.0 million; the TTM figure through Dec 2025 stood at -$78.0 million (down 11.32% YoY), while the FY2025 annual figure was -$73.9 million, down 206.79% from the prior year.
- Retained Earnings retreated to -$78.0 million in Q4 2025 per ANEB's latest filing, from -$76.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $69.2 million in Q2 2024 and bottomed at -$78.0 million in Q4 2025.
- Historically, Retained Earnings has averaged -$14.0 million across 5 years, with a median of -$42.2 million in 2021.
- Annual changes were most pronounced in 2021 — Retained Earnings soared 32880.16% — and 2022, when it tumbled 51756.92%.
- Anebulo Pharmaceuticals' Retained Earnings stood at -$41.3 million in 2021, then jumped by 263.31% to $67.4 million in 2022, then plunged by 192.58% to -$62.4 million in 2023, then retreated by 12.29% to -$70.1 million in 2024, then dropped by 11.32% to -$78.0 million in 2025.
- Business Quant data shows ANEB's Retained Earnings at -$78.0 million in Q4 2025, -$76.0 million in Q3 2025, and -$73.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 4.38 Bn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 85.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -78.00 Mn |
| Sep 30, 2025 | -76.00 Mn |
| Jun 30, 2025 | -73.89 Mn |
| Mar 31, 2025 | -71.74 Mn |
| Dec 31, 2024 | -70.07 Mn |
| Sep 30, 2024 | -67.60 Mn |
| Jun 30, 2024 | 69.19 Mn |
| Mar 31, 2024 | 69.01 Mn |
| Dec 31, 2023 | -62.40 Mn |
| Sep 30, 2023 | -59.70 Mn |
| Jun 30, 2023 | -57.20 Mn |
| Mar 31, 2023 | 67.62 Mn |
| Dec 31, 2022 | 67.40 Mn |
| Sep 30, 2022 | 67.17 Mn |
| Jun 30, 2022 | 60.51 Mn |
| Mar 31, 2022 | -43.15 Mn |
| Dec 31, 2021 | -41.27 Mn |
| Sep 30, 2021 | -40.20 Mn |
| Jun 30, 2021 | 60.03 Mn |
| Mar 31, 2021 | 83,526.00 |